Extended-Release Niacin with Laropiprant

HPS2-THRIVE trial Among patients with atherosclerotic vascular disease, the addition of extended-release niacin–laropiprant to statin-based LDL cholesterol–lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events.   Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients — NEJM.

Genetic mutation in Metabolic Syndrome

A Form of the Metabolic Syndrome Associated with Mutations in DYRK1B — NEJM.   A founder mutation was identified in DYRK1B, substituting cysteine for arginine at position 102 in the highly conserved kinase-like domain. The mutation precisely cosegregated with the clinical syndrome. Functional characterization of the disease gene revealed that nonmutant protein encoded by DYRK1B inhibits […]

TOPCAT trial

TOPCAT trial shows no benefit of spironolactone in terms of death, hospitalization, aborted SCD in heart failure with preserved ejection fraction. Spironolactone for Heart Failure with Preserved Ejection Fraction — NEJM.

%d bloggers like this: